ǥ :
|
ȣ - 500726 10 |
Long-Term Outcomes after Drug-Eluting Stent Overlapping |
계명대학교 동산의료원 심장내과¹ ,영남대학병원 순환기내과² ,인제대학교 부산 백병원 순환기내과³ |
남창욱¹, 김권배¹ ,허승호¹ ,조윤경¹ ,이상희² ,박종선² ,김영조² ,신동구² , 양태현³ ,김성만³ ,김두일³, 김동수³ |
Background: Overall deployed stent length has been reported as one of the common predictors for restenosis and poor clinical outcomes in bare metal stent. Recently, a few data showed the same results after drug-eluting stent (DES) implantation. The aim of this study is to evaluate the long-term outcomes after DES overlapping, and to compare the efficacy between sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES).
Methods: Four hundred twenty seven patients (male 65.1%, age 63±10) were consecutively enrolled in three interventional cardiology centers since April 2003 to July 2005. All the patients were divided into three groups: group 1 SESs overlap, group 2 PESs overlap, group 3 SES and PES overlap. 12 months clinical outcomes and angiographic follow-up results were analyzed.
Results: See the following table. 12months clinical follow-up was available in 100%, angiographic follow up in 53.2%.
Conclusions: SES overlapping implantation showed lower long-term adverse outcomes than PES overlapping. The incidence of adverse outcomes in overall DES overlapping (5.4%) was not different in comparing to single stent procedure. DES overlapping is relatively safe procedure in the management of long coronary lesions.
|
Table. Clinical and angiographic follow-up results
|
Group1
(SES) |
Group2
(PES) |
Group3
(S+P) |
P
value |
Patient/Stent |
310/653 |
82/188 |
35/70 |
|
Death,
(%) |
2
(0.6) |
1
(1.2) |
0
(0) |
0.750 |
MI,
(%) |
2
(0.6) |
0
(0) |
0
(0) |
0.684 |
TLR,
(%) |
10
(3.2) |
8
(9.8) |
1
(2.9) |
0.035 |
MACE,
(%) |
13
(4.2) |
9
(11.0) |
1
(2.9) |
0.042 |
ISR,
(%) |
9
(5.2) |
6
(15.8) |
2
(12.5) |
0.059 |
|
|
|